News
Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all ...
14h
Zacks.com on MSNWill Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...
According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results